Organization
Centre Henri-Becquerel and University of Rouen
5 abstracts
Abstract
Genomic profiling in a subgroup analysis of patients (pts) with diffuse large B-cell lymphoma (DLBCL) and extranodal (EN) sites of involvement in the phase 3 Pola-R-CHP versus R-CHOP (POLARIX) study.Org: Centre Henri-Becquerel and University of Rouen, University Hospital Münster, M.D. Anderson Cancer Center, Charles University General Hospital, University of Montpellier,
Abstract
Subgroup analysis of elderly patients (pts) with diffuse large B-cell lymphoma (DLBCL) in the phase 3 POLARIX study.Org: Levine Cancer Institute, Wilmot Cancer Institute, BC Cancer Centre for Lymphoid Cancer, Willamette Valley Cancer Institute and Research Center, US Oncology Research,
Abstract
Circulating tumor DNA (ctDNA) status and clinical outcomes in patients (pts) with previously untreated diffuse large B-cell lymphoma (DLBCL) in the POLARIX study.Org: City of Hope National Medical Center, Genentech, BC Cancer Centre for Lymphoid Cancer, Centre Henri-Becquerel and University of Rouen, University Hospital Münster,
Abstract
Patient- versus clinician-reported symptoms in the POLARIX study.Org: Mayo Clinic College of Medicine, Washington University School of Medicine in St Louis, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Memorial Sloan Kettering Cancer Center, Centre Henri-Becquerel and University of Rouen,
Abstract
Final analysis of the phase IB part of the LOC-R01 trial, a non-comparative randomized phase IB/II study of escalating doses of lenalidomide and ibrutinib in association with R-MPV for patients with a newly diagnosed primary central nervous system lymphoma (PCNSL).Org: Institut Curie, Saint Cloud, France, Institut Curie, Biostatistics Unit, Centre Henri-Becquerel and University of Rouen, Bergonié Institute, Neurology, Assistance Publique – Hôpitaux de Paris (APHP), Sorbonne Université, IHU, ICM, Groupe Hospitalier Pitié-Salpêtrière,